French-German Novasep-PharmaZell Group invests EUR7.3M at Mourenx site
This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.